SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekmar Group Regulatory News (TGP)

Share Price Information for Tekmar Group (TGP)

Share Price is delayed by 15 minutes
Get Live Data
15.00    0.00 (0.00%)
Bid:
14.50
Ask:
15.50
Spread: 1.00 (6.897%)
Market Cap: £20.97m
TGP Live PriceLast checked at - London Stock Exchange

Intraday Tekmar Group Share Chart

Form 8 (OPD) - TEKMAR GROUP PLC

22 Jun 2022 11:31

RNS Number : 8131P
Tekmar Group PLC
22 June 2022
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

TEKMAR GROUP PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

TEKMAR GROUP PLC

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

21 JUNE 2022

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Β 

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

NIL

Β 

NIL

Β 

(2) Cash-settled derivatives:

Β 

NIL

Β 

NIL

Β 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

NIL

Β 

NIL

Β 

Β 

TOTAL:

NIL

Β 

NIL

Β 

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

NIL

Details, including nature of the rights concerned and relevant percentages:

NIL

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Β 

DIRECTORS' INTERESTS IN SHARES

Director

Shares Held

Percentage of issued share capital

Julian Brown (Chairman)

30,341

0.05%

Alasdair MacDonald (CEO)

622,267

1.02%

Derek Bulmer (CFO)

68,297

0.11%

Ian Ritchey (NED)

33,333

0.05%

754,234

1.23%

Β 

DIRECTORS' INTERESTS IN SHARE OPTIONS

Alasdair MacDonald has options over 17,073 shares, which were granted on 20 August 2020 at nil cost and are exercisable at a price of 1p per share by 30 June 2028. The share price at the date of grant was 109p. The share options vested on 31 May 2021.

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

22 JUNE 2022

Contact name:

DEREK BULMER

Telephone number:

+44 (0)1325 349 050

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEEFZGZVGZGGZZM
Date   Source Headline
20th May 20261:42 pmRNSIssue of Equity and Total Voting Rights
7th May 20262:46 pmRNSIssue of Equity and Total Voting Rights
7th May 202612:40 pmRNSGrant of Share Options
7th May 202612:32 pmRNSGrant of Share Options
27th Apr 20263:20 pmRNSHolding(s) in Company
23rd Apr 20269:38 amRNSHolding(s) in Company
31st Mar 20262:02 pmRNSResult of AGM
31st Mar 20267:00 amRNS£2m Contract Awards on Japanese Offshore Project
9th Mar 20267:17 amRNSNotice of AGM & Publication of Annual Report
9th Mar 20267:00 amRNSFinal Results
27th Feb 20264:09 pmRNSProperty Disposal
13th Feb 202610:24 amRNS£4m Contract for European Offshore Wind Project
8th Jan 202610:28 amRNSContract Award for Logistics Port Development
18th Dec 20257:00 amRNSSecond €8m Offshore Wind Contract Award
12th Dec 20253:41 pmRNSIssue of Equity, PDMR Dealings and TVR
4th Dec 20257:00 amRNS€8m Contract, Trading Update and Investor Meeting
27th Nov 20254:55 pmRNSHolding(s) in Company
24th Nov 20253:03 pmRNSAIM Rule 17 and Schedule 2(g) Update
17th Nov 20257:00 amRNSContract in the Middle East
23rd Oct 20257:00 amRNSExercise of Options
8th Oct 202512:52 pmRNSHolding(s) in Company
8th Oct 20257:00 amRNSFramework Agreement with Jan De Nul
1st Oct 20257:00 amRNSContract Award
24th Sep 20254:46 pmRNSHolding(s) in Company
15th Sep 20255:09 pmRNSHolding(s) in Company
10th Sep 20257:00 amRNSUS$10m Contract Award
4th Sep 20252:54 pmRNSHolding(s) in Company
2nd Sep 20257:00 amRNSTrading Update
27th Aug 20257:01 amRNSReplacement: Issue of Equity and TVR
27th Aug 20257:00 amRNSResolution of Legacy Defect Notifications
26th Aug 20253:51 pmRNSIssue of Equity and Total Voting Rights
22nd Aug 202512:50 pmRNSAppointment of CFO
19th Aug 20254:06 pmRNSAIM Rule 17 and Schedule 2(g) Update
18th Aug 20257:00 amRNSNew Contract Awards
13th Aug 20257:00 amRNSDirectorate Change
9th Jul 20257:00 amRNSContract Award for Middle East Project
26th Jun 20257:00 amRNSUnaudited Interim Results
12th May 20257:00 amRNSContract Win
9th May 20251:50 pmRNSReceipt of deferred consideration
4th Apr 20256:28 pmRNSHolding(s) in Company
27th Mar 202510:20 amRNSResult of AGM
26th Mar 202511:48 amRNSGrant of Conditional Share Options
24th Mar 20253:15 pmRNSLaunch of SAYE Scheme
20th Mar 20257:00 amRNSCommercial Settlement
7th Mar 20252:11 pmRNSIssue of Equity and Total Voting Rights
6th Mar 202512:22 pmRNSHolding(s) in Company
6th Mar 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
4th Mar 20257:05 amRNSNotice of AGM & Investor Site Visit
4th Mar 20257:00 amRNSFinal Results
18th Feb 20257:00 amRNSThree-Year Framework Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.